Correlation between virulence genotype and fluoroquinolone drugs resistance in Pseudomonas aeruginosa of lower respiratory tract infection
JU Xiao-hong1, LI Yao1, WANG Yue-hua1, ZHAO Peng-bo2
1. Academy of Laboratory, Jilin Medical University, Jilin 132013, China; 2. Department of Clinical Laboratory, Jilin Provincial People's Hospital, Jilin 132000, China
Abstract:We investigated the correlation between toxin gene exoS,exoU and fluoroquinolone resistance in lower respiratory tract infection with P. aeruginosa so as to provide guidance for reasonable treatment of clinical infections. We collected P. aeruginosa of sputum samples in hospitalized patients from October 2015 to March 2016.The antimicrobial susceptibility was tested by liquid dilution method.The exoS and exoU genes were detected by PCR technique. Results showed that forty-six P. aeruginosa strains were identified from sputum. The exoS and exoU gene positive rate were 86.96%(40/46) and 69.57%(32/46) respectively, and the highest proportion of genotype was exoS+/exoU+(60.87%,28/46). Among them, 36.96% (17/46) were multiple drug-resistant bacteria(MDR). Fluoroquinolone non-sensitive (FQ-NS) strain were 78.95% (15/19) for MDR and 89.47%(17/19) exoU gene were positive, which was significantly higher than the fluoroquinolone sensitive strains (FQ-S). Compared with the FQ-S strain, FQ-NS strains were serious drug resistance. The drug resistant rate of cefepime and aztreonam were more than 70%, and then meropenem and imipenem were more than 50%. The drugs of lower resistance rate in FQ-NS strain had polymyxin B(10.53%,2/19), amikacin(10.53%,2/19), ceftazidime(15.79%,3/19) and gentamicin (21.05%,4/19). P. aeruginosa of lower respiratory infection carried toxin genes exoS and exoU were higher, the main genetpy was exoS+/exoU+.FQ-NS strains were higher drug resistance rate and a higher proportion of exoU+ strains than FQ-S strains. We should strengthen virulence genes test and drug resistance monitoring in clinical practice.
鞠晓红, 李瑶, 王月华, 赵蓬波. 下呼吸道感染来源铜绿假单胞菌毒力基因与氟喹诺酮类药物的耐药性研究[J]. 中国人兽共患病学报, 2017, 33(1): 38-42.
JU Xiao-hong, LI Yao, WANG Yue-hua, ZHAO Peng-bo. Correlation between virulence genotype and fluoroquinolone drugs resistance in Pseudomonas aeruginosa of lower respiratory tract infection. Chinese Journal of Zoonoses, 2017, 33(1): 38-42.
[1] Ye YW, Wang YS, Shen ZY. National guide to clinical laboratory procedures[S]. Third Edition.Nanjing: Southeast University Publishing House, 2006: 744-745.(in Chinese) 叶应妩,王毓三,申子瑜.全国临床检验操作规程[S].3版.南京: 东南大学出版社,2006:744-745. [2] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twenty-Fourth Informational Supplement, 2014. [3] Ding YL, Chen YH, Yao WZ, et al. Analysis of antimicrobial resistance of multidrug resistant Pseudomonas aeruginosa [J]. Chin J Antibiotics, 2012, 37(1): 63-67.(in Chinese) 丁艳苓,陈亚红,姚婉贞,等.多重耐药铜绿假单胞菌的耐药性分析[J].中国抗生素杂志, 2012,37(1): 63-67. [4] Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa [J]. Microbiology, 2001, 147(10): 2659-2669. doi:10.1099/00221287-147-10-2659 [5] Cho HH, Kwon KC, Kim S, et al. Correlation between virulence genotype and fluoroquinolone resistance in carbapenem-resistant Pseudomonas aeruginosa [J]. Ann Lab Med, 2014, 34(4): 286-292. doi:10.3343/alm.2014.34.4.286 [6] Wong-Beringer A, Wiener-Kronish J, Lynch S, et al. Comparison of type Ⅲ secretion system virulence among fluoroquinolone-susceptible and resistant clinical isolates of Pseudomonas eruginosa [J]. Clin Microbiol Infect, 2008, 14(4): 330-336. doi:10.1111/j.1469-0691.2007.01939.x [7] Garey KW, Vo QP, Larocco MT, et al. Prevalence of type III secretion system protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa [J]. J Chemother, 2008, 20(6): 714-720. doi:10.1179/joc.2008.20.6.714 [8] Maatallah M, Cheriaa J, Backhrouf A, et al. Population structure of Pseudomonas aeruginosa from five mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235[J]. PLoS One, 2011, 6(10): e25617. doi:10.1371/j.pone.0025617 [9] Galle M, Carpentier I, Beyaert R. Structure and function of the type III secretion system of pseudomonas aeruginosa [J]. Curr Protein Pept Sci, 2012, 13(8): 831-842. [10] Howell HK, Logan LK, Hausera AR. Type III secretion of ExoU is critical during early pseudomonas aeruginosa pneumonia[J]. MBio, 2013, 4(2): e00032. doi:10.1128/mBio.00032-13 [11] Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa [J]. PLOS One, 2012, 7(8): e42973. doi:10.1371/j.pone.0042973 [12] Flamm RK, Weaver MK, Thornsberry C, et al. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginos isolates tested in clinical laboratories in the United States from 1999 to 2002[J]. Antimicrob Agents Chemother, 2004, 48(7): 2431-2436. doi:10.1128/AAC.48.7.2431-2436.2004 [13] Hau DI, Okamoto MP, Murthy R, et al. Fluoroquinolone-resistant Pseudomonas aeruginosa : risk factors for acquisition and impact on outcomes[J]. J Antimicrob Chemother, 2005, 55(4): 535-541. doi:10.1093/jac/dki026. [14] Zhang GD, Zeng ZR, Wang Y, et al. Mechanisms of gyrA,gyrB and efflux system jointly mediating quinlone resistance in clinical isolates of Pseudomonas aeruginosa [J]. Chin J Infect Chemother, 2014, 14(3): 224-228.(in Chinese) 张国栋,曾章锐,王莹,等. gyrA 、 gyrB 和外排系统共同介导铜绿假单胞菌对喹诺酮类耐药机制研究[J].中国感染与化疗杂志,2014,14(3): 224-228. [15] Zeng ZR, Shao HF, Wang WP, et al. Study on mechanism of imipenem resistance of ephalosporin-susceptible or intermediate Pseudomonas aeruginosa [J]. Chin J Clin Lab Sci,2013, 31(1): 24-27.(in Chinese) 曾章锐,邵海枫,王卫萍,等.头孢菌素敏感或中介的铜绿假单胞菌对亚胺培南耐药机制的研究[J].临床检验杂志,2013,31(1): 24-27.